Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters

Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters

Introduction: Chronic hepatitis C (CHC) is a clinical and pathological syndrome with various causes and is characterized by varying degrees of hepatocellular necrosis and inflammation. It is a significant cause of liver transplantation and liver-related death worldwide. The hepatic manifestations of...

Full description

Bibliographic Details
Main Authors:	Joana Ferreira, Manuel Bicho, Fátima Serejo
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Viruses
Subjects:	chronic hepatitis C fibrosis metabolic profile direct-acting antivirals
Online Access:	https://www.mdpi.com/1999-4915/16/3/371

Similar Items

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
by: Ramy H. Agwa, et al.
Published: (2022-02-01)

Evaluation of HCV-related liver fibrosis post-successful DAA therapy
by: Nermine Ehsan, et al.
Published: (2021-06-01)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
by: Naim Abu-Freha, et al.
Published: (2023-09-01)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
by: Ibrahim Anam Ezzelregal, et al.
Published: (2020-10-01)

No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients
by: Julio Collazos, et al.
Published: (2024-03-01)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01)

Status of liver stiffness following directly acting antiviral treatment in patients with chronic hepatitis C: A Nepalese study
by: Dilip Sharma, et al.
Published: (2017-10-01)

Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8+ T-Cells in Advanced Liver Disease
by: Agatha Vranjkovic, et al.
Published: (2019-08-01)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
by: Christiana Graf, et al.
Published: (2020-08-01)

Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment
by: Joana Ferreira, et al.
Published: (2023-01-01)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
by: Hafiza Arooba Riaz, et al.
Published: (2023-05-01)

Direct-acting antiviral therapy may help restore HCV-induced impaired redox balance and liver fibrosis process
by: Bal Tayibe, et al.
Published: (2022-11-01)

Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients
by: Paula Fernández-Alvarez, et al.
Published: (2023-05-01)

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
by: Gustavo H. Pereira, et al.
Published: (2022-09-01)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
by: Julia L. Casey, et al.
Published: (2019-04-01)

Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice
by: Mayadah M. Abdelsalam, et al.
Published: (2023-03-01)

Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response
by: Alejandro García-Ros, et al.
Published: (2023-04-01)

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis
by: JiHyun An, et al.
Published: (2022-09-01)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
by: A. Maughan, et al.
Published: (2019-05-01)

Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection
by: Stephan R. Marticorena Garcia, et al.
Published: (2021-02-01)

Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)
by: Waleed Attia Hassan, et al.
Published: (2023-10-01)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
by: Luca Rinaldi, et al.
Published: (2020-05-01)

Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome
by: Zeinab Soliman, et al.
Published: (2021-04-01)

Response to Interferon-Free Direct Antivirals (DAAS) Treatment in HCV-Related Subcutaneous Lipoma-Like Marginal Zone B-Cell Lymphoma
by: Maria Lucia De Luca, et al.
Published: (2019-08-01)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
by: Kazuto Tajiri, et al.
Published: (2023-05-01)

Association between Liver Stiffness and Liver-Related Events in HCV-Infected Patients after Successful Treatment with Direct-Acting Antivirals
by: Napas Rodprasert, et al.
Published: (2023-03-01)

IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy
by: Abdelfattah M. Attallah, et al.
Published: (2021-10-01)

Shear Wave Elastography for Assessing Liver Stiffness in HCV-Infected Kidney Transplant Recipients after Direct-Acting Antiviral Treatment: A Comparative Study with Magnetic Resonance Elastography
by: Salma Almutawakel, et al.
Published: (2023-12-01)

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis
by: Mario G. Pessoa, et al.
Published: (2018-11-01)

Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era
by: Huma Saeed, et al.
Published: (2022-11-01)

Anti-HCV DAA are needed whatever liver fibrosis is. The cons
by: Pablo Barreiro
Published: (2016-05-01)

Anti-HCV DAA are needed whatever liver fibrosis is. The pros
by: Albert Tran
Published: (2016-05-01)

Outcomes of liver transplantation in the era of modern antiviral therapy for hepatitis C
by: K. Yu. Kokina, et al.
Published: (2021-04-01)

Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection
by: Sergio Ferra-Murcia, et al.
Published: (2022-05-01)

Perceived Stress in Hepatitis C Virus Infected Patients under the DAA-Based Therapy
by: Claudia Monica Danilescu, et al.
Published: (2022-05-01)

HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV
by: Kilian Weigand, et al.
Published: (2022-12-01)

Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy
by: Roberto Ravasio, et al.
Published: (2020-12-01)

Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy
by: Claudia Monica Danilescu, et al.
Published: (2021-11-01)